ABSTRACT
PURPOSE: Carbapenem resistant Pseudomonas aeruginosa (CR-PA) is escalating worldwide and leaves clinicians few therapeutic options in recent years, ß-lactam/ß-lactamase inhibitor combinations (ceftolozane-tazobactam, ceftazidime-avibactam) and a new siderophore cephalosporin (cefiderocol) have been approved for the treatment of P. aeruginosa infection and have shown potent activity against isolates defined as carbapenem resistant. The aim of this study was to determine the phenotypic profile of these agents against CR-PA in the emerging setting of carbapenemases. METHODS: CR-PA clinical isolates were collected from three teaching hospitals in different geographical regions between January 2017-December 2021. All isolates were subjected to phenotypic carbapenemase testing using modified carbapenem inactivation method. MICs were determined by reference broth microdilution and evaluated according to EUCAST standards, while genotypic profiling was determined using PCR methods. RESULTS: 244 CR-PA sourced most frequently from the respiratory tract (32.2%), blood (20.4%) and urine (17.5%) were evaluated. Of all isolates, 32 (13.1%) were phenotypically and 38 (15.6%) were genotypically defined as carbapenemase-positive. The most common carbapenemase was GES (63.1%), followed by VIM (15.8%). The MIC50/90(S%) of ceftazidime/avibactam, ceftolozane/tazobactam and cefiderocol in all CR-PA isolates were 4 and 32 (80%), 1 and > 64 (69%) and 0.25 and 1 mg/L (96%), respectively. Cefiderocol was also the most active agent in carbapenemase-positive isolates (90%). CONSLUSION: While ceftolozane/tazobactam and ceftazidime/avibactam remained highly active against CR-PA devoid of carbapenemases, cefiderocol provided potent in vitro activity irrespective of carbapenemase production. When considering the potential clinical utility of newer agents against CR-PA, regional variations in carbapenemase prevalence must be considered.
Subject(s)
Anti-Bacterial Agents , Azabicyclo Compounds , Cefiderocol , Ceftazidime , Cephalosporins , Drug Combinations , Microbial Sensitivity Tests , Pseudomonas Infections , Pseudomonas aeruginosa , Tazobactam , Humans , Cephalosporins/pharmacology , Ceftazidime/pharmacology , Azabicyclo Compounds/pharmacology , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/isolation & purification , Pseudomonas aeruginosa/genetics , Pseudomonas aeruginosa/enzymology , Pseudomonas Infections/microbiology , Tazobactam/pharmacology , Anti-Bacterial Agents/pharmacology , Middle Aged , Female , Male , Adult , beta-Lactamases/genetics , beta-Lactamases/metabolism , Aged , Carbapenems/pharmacology , Bacterial Proteins/genetics , Young Adult , Adolescent , beta-Lactamase Inhibitors/pharmacology , ChildABSTRACT
Upon the observation of an increase in teicoplanin resistance rates in coagulase negative staphylococci (CoNS) isolates determined by the automated system, we aimed to compare the automated system and gradient test methods with the gold standard broth microdilution method. In addition, the effect of standard antimicrobial susceptibility guidelines on teicoplanin susceptibility test results in CoNS was investigated. A total of 81 CoNS isolates, 52 resistant and 29 susceptible to teicoplanin determined by automated system (Phoenix, Becton Dickinson, USA), were tested. The minimum inhibitory concentration (MIC) values were determined by gradient test (M.I.C. Evaluators, OXOID, UK) and broth microdilution methods. Susceptibility categories were determined according to EUCAST and CLSI criteria and the results were compared. Among 29 isolates found to be susceptible by automated system, one isolate was found resistant by gradient and broth microdilution tests. Of the 52 resistant isolates determined by automated system, 12 (23%) were found to be resistant by gradient test and 22 (42.3%) were resistant by broth microdilution. According to CLSI criteria, no resistant isolates were detected by broth microdilution and six isolates were intermediately susceptible while, two isolates were detected to be resistant and five isolates were found to be intermediately susceptible by the gradient test. In conclusion, compared to microdilution, teicoplanin resistance was detected at a higher rate in CoNS isolates by the automated system used. On the other hand, the gradient test method which is frequently used for confirmation was not reliable in MIC values close to the EUCAST breakpoint values (4 µg/mL). In addition, lower resistance rates were observed when the CLSI breakpoints were used in gradient test and broth microdilution methods.
Subject(s)
Coagulase , Teicoplanin , Anti-Bacterial Agents/pharmacology , Microbial Sensitivity Tests , Staphylococcus , Teicoplanin/pharmacologyABSTRACT
INTRODUCTION: The diagnosis of streptococcal pharyngitis is very important to prevent complications such as acute rheumatic fever. Throat culture is the gold standard method for the diagnosis of streptococcal pharyngitis, however, rapid antigen tests (RAT) have been developed for faster diagnosis. The purpose of this study is to evaluate the efficacy of the BD Veritor ™ System (USA) rapid antigen assay in detecting Group A Streptococcus (GAS) in throat swab samples. METHODS AND MATERIALS: A total of 12,391 throat swabs, taken with a double swab, were evaluated. The BD Veritor ™ System was used for the detection of GAS antigen. Simultaneous throat cultures were performed. RESULTS: Throat culture yielded positive for 18.5% (2291) while 19.1% (2369) were positive with RAT. The sensitivity of BD Veritor ™ System was determined as 94.1% and specificity as 97.9%, while positive predictive value, negative predictive value and accuracy were determined as 91.0%, 98.7%, 97%, respectively. When all age groups were included, the rate of GAS positivity was 18.5% and this ratio increased to 27.3% in the five-15 age group. CONCLUSION: Our study, conducted with quite a large number of patients, yielded high sensitivity for the BD Veritor System. When the RAT is negative, the necessity of culture for pediatric patients should not be forgotten.